| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 國立成功大學 |
2022 |
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
|
Wu, Y.-L.;Lu, S.;Yang, J.C.-H.;Zhou, J.;Seto, T.;Ahn, M.-J.;Su, W.-C.;Yamamoto, N.;Kim, D.-W.;Paolini, J.;Usari, T.;Iadeluca, L.;Wilner, K.D.;Goto, K. |
| 臺大學術典藏 |
2021-11-03T02:32:59Z |
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non?small cell lung cancer
|
Nakagawa K.; Nadal E.; Garon E.B.; Nishio M.; Seto T.; Yamamoto N.; Park K.; JIN-YUAN SHIH; Paz-Ares L.; Frimodt-Moller B.; Zimmermann A.H.; Wijayawardana S.; Visseren-Grul C.; Reck M. |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators |
| 臺大學術典藏 |
2021-04-23T05:56:32Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Chih-Hsin Yang;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Cheng J.C.-H.;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y.; Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; CHIH-HSIN YANG; Wang J.; Babu K.G.; Nakayama Y.; Alip A.; Chua K.L.M.; Cheng J.C.-H.; Senan S.; Ahn Y.C.; Kim T.-Y.; Ahn H.K.; Peters S.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
|
Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
|
Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:34:59Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
